iifl-logo

Shilpa Medicare Ltd Board Meeting

915.1
(0.07%)
Jun 9, 2025|01:39:56 PM

Shilpa Medicare CORPORATE ACTIONS

10/06/2024calendar-icon
10/06/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting26 May 202519 May 2025
Pursuant to the provisions of Regulation 29 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby wish to inform you that the Meeting of the Board of Directors of Shilpa Medicare Limited is scheduled on Monday, 26 May 2025 inter alia to consider and approve the following: (a) audited financial statements (Consolidated & Standalone) for the financial year ending March 31, 2025 (b) audited financial results (Consolidated & Standalone) for the quarter and financial year ending March 31, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (c ) recommendation of dividend, if any for the Financial Year 2024-25. BM outcome (As Per BSE Announcement Dated on: 26/05/2025)
Board Meeting10 Feb 20253 Feb 2025
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve The Meeting of Board of Directors of the Company will be held on Monday 10 February 2025 to inter alia consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December 2024. In terms of the Code of Conduct for Prevention of Insider Trading in Securities of the Company the Trading Window has been closed with effect from 1 January 2025 and remains closed upto 48 hours after the declaration of Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December 2024 BM outcome Integrated filing (As Per BSE Announcement Dated on 10/02/2025)
Board Meeting13 Nov 20244 Nov 2024
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30 September 2024 Considered and approved 1.The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2024. A copy of Un-Audited Financial Result along with the Limited Review report is enclosed as Annexure 1. 2.Inducted Dr. Anita Bandyopadhyay, Non-Executive Independent Director as a member of Audit Committee. (As Per BSE Announcement dated on 13.11.2024)
Board Meeting8 Aug 202431 Jul 2024
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Intimation of Board Meeting to consider the Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30 June 2024 Unaudited financial results for the quarter ended 30th June, 2024 Revised outcome of the Board meeting held on 08 August 2024 Outcome of Board Meeting (As per BSE Announcement Dated on 08/08/2024)

Shilpa Medicare: Related News

Shilpa Medicare Receives EU GMP Approval for Bengaluru Manufacturing Unit
8 May 2025|12:30 AM

The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025

Read More
Shilpa Medicare Strikes Global Immuno-Oncology Deal with mAbTree
18 Mar 2025|01:22 PM

The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.

Read More
Top Stocks for Today - 18th March 2025
18 Mar 2025|06:44 AM

Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.

Read More
Shilpa Pharma Lifesciences Clears USFDA Inspection at Raichur Unit-2
16 Mar 2025|11:29 PM

No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.

Read More
Shilpa Medicare Gets CDSCO Nod for NAFLD Drug
13 Feb 2025|11:09 PM

Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.

Read More
Shilpa Medicare Secures EU GMP Certification for Hyderabad Facility
23 Dec 2024|01:30 PM

The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.

Read More
Shilpa Medicare’s JV Oncosol Gets FDA Nod for IMKELDI
28 Nov 2024|12:41 AM

This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.

Read More
Shilpa Medicare Secures Phase III Trial Nod for Recombinant Albumin
26 Nov 2024|07:49 PM

  Shilpa Medicare is the first Indian company to gain approval for Phase III trials of Recombinant Human Albumin.

Read More
Shilpa Medicare Subsidiary Bags European Certification for Nifedipine
19 Nov 2024|05:28 PM

The European Directorate for the Quality of Medicines & Healthcare (EDQM) gave Shilpa Pharma Lifesciences, the company's subsidiary, the Certificate of Suitability (CEP) for Nifedipine.

Read More
Top 10 stocks for today - 4th October, 2024
4 Oct 2024|08:46 AM

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.